PHARMACEUTICAL

Incentives & Values Proposition

01

Access to largest GCC market valued at US$ 5.1 billion in 2012 with over 85% of vaccines imported and health budget over SAR 50 billion.

02

Proximity to King Abdullah University of Science and Technology (KAUST) to facilitates the development of innovation in pharmaceutical industry with R&D centers.

03

CADRE providing full sponsorship to foreign employees with low labor cost with NO income tax for individuals.

04

Preferential government treatment for local manufacturers granted through the SFDA.

05

The first zone dedicated for Pharma and clean industries in Saudi and strong environmental standards.

06

Low energy and transportation costs.

PHARMACEUTICAL TENANTS

PHARMACEUTICAL TESTIMONIALS

PHILIPPE LUSCAN

“Our decision to go ahead with this project was due entirely to the highly encouraging and supportive investment environment provided by KAEC, and the economic strength and solidity of the Kingdom of Saudi Arabia”

Senior Vice President for Industrial Affairs, Sanofi

HUSSEIN EL HAKIM

“Bringing Pfizer manufacturing facility project from agreement to execution and reality was commitment we made when we first inked the project agreement with SAGIA and KAEC to help respond to these growing needs”

Country Manager, Pfizer Saudi Arabia

YASSER BIN YOUSSEF

“We choose KAEC because its strategic location on the Read Sea. Industrial Valley, being directly linked to King Abdullah Port.”

Owner, Cigalah Group